Ascendis Pharma Ownership
| ASND Stock | USD 127.70 5.06 4.13% |
Shares in Circulation | First Issued 2013-12-31 | Previous Quarter 57.3 M | Current Value 57.3 M | Avarage Shares Outstanding 40.7 M | Quarterly Volatility 14.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Ascendis |
Ascendis Stock Ownership Analysis
About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 7.86. Ascendis Pharma AS had not issued any dividends in recent years. Ascendis Pharma AS, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. Ascendis Pharma is traded on NASDAQ Exchange in the United States. For more info on Ascendis Pharma AS please contact Jan Mikkelsen at 45 70 22 22 44 or go to https://ascendispharma.com.Besides selling stocks to institutional investors, Ascendis Pharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Ascendis Pharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Ascendis Pharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Ascendis Pharma Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Ascendis Pharma AS are currently held by insiders. Unlike Ascendis Pharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Ascendis Pharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Ascendis Pharma's insider trades
Ascendis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ascendis Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ascendis Pharma AS backward and forwards among themselves. Ascendis Pharma's institutional investor refers to the entity that pools money to purchase Ascendis Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.8 M | Amvescap Plc. | 2024-06-30 | 1.1 M | Adage Capital Partners Gp Llc | 2024-06-30 | 820.5 K | Vestal Point Capital Lp | 2024-06-30 | 750 K | Sofinnova Ventures | 2024-06-30 | 734.3 K | Camber Capital Management Llc | 2024-09-30 | 700 K | Ameriprise Financial Inc | 2024-06-30 | 660.7 K | Spyglass Capital Management Llc | 2024-09-30 | 652.8 K | Citadel Advisors Llc | 2024-06-30 | 537.8 K | Ra Capital Management, Llc | 2024-06-30 | 10.1 M | Westfield Capital Management Company, Lp | 2024-09-30 | 5.1 M |
Ascendis Pharma's latest congressional trading
Congressional trading in companies like Ascendis Pharma AS, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Ascendis Pharma by those in governmental positions are based on the same information available to the general public.
| 2018-11-07 | Representative Gary Palmer | Acquired Under $15K | Verify |
Ascendis Pharma Outstanding Bonds
Ascendis Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ascendis Pharma AS uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ascendis bonds can be classified according to their maturity, which is the date when Ascendis Pharma AS has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ASCENSION HEALTH Corp BondUS04352EAA38 | View | |
| US04352EAB11 Corp BondUS04352EAB11 | View | |
| ASCENSION HEALTH ALLIANCE Corp BondUS04351LAB62 | View | |
| US04351LAA89 Corp BondUS04351LAA89 | View |
Ascendis Pharma Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
6K | 13th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 20th of September 2024 Other Reports | ViewVerify | |
| 18th of September 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.86) | Revenue Per Share 5.595 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (8.18) |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.